Diosmin: Difference between revisions
→Diosmiplex: Restore the scientific name, adequately referenced + add working group guidelines |
m →Uses: wikilink |
||
Line 48: | Line 48: | ||
==Uses== |
==Uses== |
||
Diosmin is a dietary supplement used to aid treatment of [[hemorrhoid]]s and venous diseases, i.e., [[chronic venous insufficiency]] including spider and varicose veins, leg swelling ([[edema]]), [[stasis dermatitis]] and [[venous ulcer]]s.<ref name="drugs">{{cite web |title=Diosmin |url=https://www.drugs.com/npp/diosmin.html |publisher=Drugs.com |accessdate=7 November 2019 |date=1 January 2019}}</ref> A 2016 Cochrane review found only moderate-quality evidence that diosmin or other compounds called |
Diosmin is a dietary supplement used to aid treatment of [[hemorrhoid]]s and venous diseases, i.e., [[chronic venous insufficiency]] including spider and varicose veins, leg swelling ([[edema]]), [[stasis dermatitis]] and [[venous ulcer]]s.<ref name="drugs">{{cite web |title=Diosmin |url=https://www.drugs.com/npp/diosmin.html |publisher=Drugs.com |accessdate=7 November 2019 |date=1 January 2019}}</ref> A 2016 Cochrane review found only moderate-quality evidence that diosmin or other compounds called [[phlebotonic]]s improved leg and ankle swelling and lower leg pain.<ref name="Cochrane2016">{{cite journal |last1=Martinez-Zapata |first1=Maria José |last2=Vernooij |first2=Robin WM |last3=Uriona Tuma |first3=Sonia Maria |last4=Stein |first4=Airton T |last5=Moreno |first5=Rosa M |last6=Vargas |first6=Emilio |last7=Capellà |first7=Dolors |last8=Bonfill Cosp |first8=Xavier |title=Phlebotonics for venous insufficiency |journal=Cochrane Database of Systematic Reviews |date=6 April 2016 |doi=10.1002/14651858.CD003229.pub3 |pmid=27048768}}</ref> |
||
Its mechanism of action is undefined,<ref name=drugs/> and [[evidence-based medicine|clinical evidence]] of benefit is limited.<ref name=drugs/> Diosmin is not recommended for treating the [[rectum|rectal mucosa]], skin irritations, or wounds, and should not be used to treat [[dermatitis]], [[eczema]], or [[urticaria]].<ref name=drugs/> Diosmin is not recommended for use in children or women during [[pregnancy]].<ref name=drugs/> |
Its mechanism of action is undefined,<ref name=drugs/> and [[evidence-based medicine|clinical evidence]] of benefit is limited.<ref name=drugs/> Diosmin is not recommended for treating the [[rectum|rectal mucosa]], skin irritations, or wounds, and should not be used to treat [[dermatitis]], [[eczema]], or [[urticaria]].<ref name=drugs/> Diosmin is not recommended for use in children or women during [[pregnancy]].<ref name=drugs/> |
||
==Adverse effects== |
==Adverse effects== |
Revision as of 03:29, 8 November 2019
Clinical data | |
---|---|
AHFS/Drugs.com | International Drug Names |
Routes of administration | oral |
ATC code | |
Identifiers | |
| |
CAS Number | |
PubChem CID | |
DrugBank | |
ChemSpider | |
UNII | |
KEGG | |
ChEBI | |
ChEMBL | |
CompTox Dashboard (EPA) | |
ECHA InfoCard | 100.007.537 |
Chemical and physical data | |
Formula | C28H32O15 |
Molar mass | 608.545 g/mol g·mol−1 |
3D model (JSmol) | |
| |
| |
(what is this?) (verify) |
Diosmin (diosmetin 7-O-rutinoside), a flavone glycoside of diosmetin, is manufactured from citrus fruit peels as a non-prescription dietary supplement used to aid treatment of hemorrhoids or chronic venous diseases, mainly of the legs.[1]
Uses
Diosmin is a dietary supplement used to aid treatment of hemorrhoids and venous diseases, i.e., chronic venous insufficiency including spider and varicose veins, leg swelling (edema), stasis dermatitis and venous ulcers.[1] A 2016 Cochrane review found only moderate-quality evidence that diosmin or other compounds called phlebotonics improved leg and ankle swelling and lower leg pain.[2]
Its mechanism of action is undefined,[1] and clinical evidence of benefit is limited.[1] Diosmin is not recommended for treating the rectal mucosa, skin irritations, or wounds, and should not be used to treat dermatitis, eczema, or urticaria.[1] Diosmin is not recommended for use in children or women during pregnancy.[1]
Adverse effects
In some 10% of users, diosmin causes mild gastrointestinal disorders or skin irritations (hives, itching), stomach pain, nausea, heart arrhythmias, or anemia.[1] Preliminary research indicates there is no indication of toxicity.[1] The US Food and Drug Administration (FDA) concluded in 2001 that there was inadequate evidence on which to base an expectation of safety.[3] As of 2013[update], the FDA did not revise this position.[4]
Regulatory status
Diosmin is distributed in the U.S. as a dietary supplement called Daflon.[1] Diosmin or any phlebotonic agent is not approved as a prescription drug in the United States or Europe.[1]
Diosmiplex
Micronized purified flavonoid fraction (generic name diosmiplex, commercial name Vasculera)[5] is a 2nd generation diosmin classified as a medical food by the FDA in the United States for the potential treatment of chronic venous insufficiency.[6] Diosmiplex is the only phlebotonic, as of 2017[update], sold as a medical food product purported for the management of chronic venous insufficiency.[5] Diosmiplex is recommended by the American Working Group in Chronic Venous Disease as a medical therapy, alone or combined with compressive therapy, for chronic venous disease and venous ulcers, having "beneficial outcomes without serious adverse events", concurring with the previous guidance of the International European Society for Vascular Surgery.[5]
See also
References
- ^ a b c d e f g h i j "Diosmin". Drugs.com. 1 January 2019. Retrieved 7 November 2019.
- ^ Martinez-Zapata, Maria José; Vernooij, Robin WM; Uriona Tuma, Sonia Maria; Stein, Airton T; Moreno, Rosa M; Vargas, Emilio; Capellà, Dolors; Bonfill Cosp, Xavier (6 April 2016). "Phlebotonics for venous insufficiency". Cochrane Database of Systematic Reviews. doi:10.1002/14651858.CD003229.pub3. PMID 27048768.
- ^ New Dietary Ingredients in Dietary Supplements, U. S. Food and Drug Administration Center for Food Safety and Applied Nutrition Office of Nutritional Products, Labeling, and Dietary Supplements February 2001 (Updated September 10, 2001) [1], Memorandum [2]
- ^ Garg, Nitin; Gloviczki, Peter (2013). "55 - Chronic Venous Insufficiency". Vascular Medicine: A Companion to Braunwald's Heart Disease (Second Edition). Elsevier Health Sciences. pp. 652–666. ISBN 9781437729306.
- ^ a b c Bush, R; Comerota, A; Meissner, M; Raffetto, JD; Hahn, SR; Freeman, K (April 2017). "Recommendations for the medical management of chronic venous disease: The role of Micronized Purified Flavanoid Fraction (MPFF): Recommendations from the Working Group in Chronic Venous Disease (CVD) 2016". Phlebology (Professional society guidelines). 32 (1_suppl): 3–19. doi:10.1177/0268355517692221. PMID 28211296.
Only recently has a standardized formulation MPFF been available in the United States (Vasculera—Primus Pharmaceuticals, Inc.).
- ^ "Vasculera". Drugs.com. 3 December 2018. Retrieved 7 November 2019.